MedPath

ABRYSVO

ABRYSVO

Approved
DIN Number

02544040

Drug Class

Human

Market Date

May 22, 2024

Company
HC

Pfizer Canada Ulc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02544040
AIG Number0265562001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D
A
ATC Code
J07BX05 RESPIRATORY SYNCYTIAL VIRUS VACCINE
Product Specifications
Dosage FormPowder For Solution ,  Kit
Route of AdministrationIntramuscular
AHFS Classification80:12.00
Health Canada Classification

ACTIVE INGREDIENTS (2)

RSV SUBGROUP A STABILIZED PREFUSION F PROTEINActive
Strength: 60 MCG / 0.5 ML
Monograph: RSV SUBGROUP A STABILIZED PREFUSION F PROTEIN
RSV SUBGROUP B STABILIZED PREFUSION F PROTEINActive
Strength: 60 MCG / 0.5 ML
Monograph: RSV SUBGROUP B STABILIZED PREFUSION F PROTEIN

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.